Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir for mild COVID-19 in outpatients
IRCT20201127049505N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Standard of care with Sofosbuvir + standard of care (2 arms). Primary endpoint: Clinical recovery (composite) within 14 days. Started Dec 2020; status: completed.
02
Drugs
sofosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20201127049505N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201127049505N1.